Author:
Abualfraj Abdulelah,Ismail Ammar,Aljabarti Azzah,Jamjoom Maan
Publisher
Discover STM Publishing Ltd.
Reference10 articles.
1. Machu TK. Therapeutics of 5-HT3 receptor antagonists: current uses and future directions. Pharmacol Ther. 2011;130(3):338-47. https://doi.org/10.1016/j.pharmthera.2011.02.003
2. Haus U, Späth M, Färber L. Spectrum of use and tolerability of 5-HT3receptor antagonists Scand J Rheumatol. 2009;(33):12-8. https://doi.org/10.1080/03009740410006961
3. Boike SC, Ilson B, Zariffa N, Jorkasky DK. Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am J Health Syst Pharm. 1997;54(10):1172-6. https://doi.org/10.1093/ajhp/54.10.1172
4. Cakir FB, Yapar O, Canpolat C, Akalin F, Berrak SG. Cardiac effects of granisetron in a prospective crossover randomized dose comparison trial. Support care cancer Off J Multinatl Assoc Support Care Cancer. 2012;20(10):2451-7. https://doi.org/10.1007/s00520-011-1376-5
5. Alidoosti A, Taslimi F, Ameri A, Khosro MS, Miri R, Yavari P. Electrocardiographic changes after granisetron administration for chemotherapy induced nausea and vomiting. Acta Med Iran [Internet]. 1970;47(4 SE-Articles). Available from: http://acta.tums.ac.ir/index.php/acta/article/view/3593